By admin | Published:
August 29, 2007
Nilesh Samani
REFERENCE: N Engl J Med 2007; 357: 443-53
NILESH SAMANI, University of Leicester UK
Previously unrecognised DNA segments in human genes have been found to significantly increase the risk of coronary artery disease. That’s according to a publication just out in the New England Journal of Medicine. Nilesh Samani from the University of Leicester explained how this will help identify new high-risk groups and target prevention before the disease develops in at risk individuals.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 23, 2007
Kypros Nicolaides
REFERENCE: N Engl J Med 2007; 357: 426-9
KYPROS NICOLAIDES, Kings College Hospital, London
The risk of giving birth prematurely was reduced among pregnant women with short cervices by treatment with vaginally administered progesterone: whether or not they had a history of preterm delivery. Investigators from London have reported in the New England Journal of Medicine that progesterone therapy significantly reduced the risk of spontaneous delivery before 34 weeks: from a one in three chance with a placebo to one in five with progesterone. Kypros Nicolaides discussed the results with Anna Lacey.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 15, 2007
Ludwig Kappos
REFERENCE: Lancet 2007; 370: 389-97
LUDWIG KAPPOS, University Hospital, Basel
Earlier treatment can reduce the risk of confirmed disability in patients with multiple sclerosis, according to a new study published in the Lancet. Three-year follow-up of the BENEFIT study showed favourable results among patients who began treatment with interferon beta-1b after a first event suggestive of multiple sclerosis, rather than waiting for further confirmatory events. Nicola Solomon interviewed Ludwig Kappos.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 14, 2007
Sherman Silber
REFERENCE: O-149
SHERMAN SILBER, St Luke’s Hospital, St Louis MO
A study from Missouri has shown that transplanting intact ovaries using microvascular surgical techniques is superior in the long term for restoring or preserving fertility to the simpler technique known as cortical grafting. Sarah Maxwell heard about the findings from Sherman Silber during the fertility conference held in Lyon.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 14, 2007
Saad Amer
REFERENCE: O-148
SAAD AMER, The Derby Medical School, Nottingham University
More reassurance about the use of clomifene for treating anovulatory women with polycystic ovarian syndrome has emerged from a randomised study from Nottingham reported to the fertility conference held in Lyon. Laparoscopic ovarian diathermy, normally used as second line treatment (after clomifene), was found to be equivalent for inducing ovulation and pregnancy in a study with over sixty women. But Saad Amer explained to Sarah Maxwell why he still favours clomifene.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 14, 2007
&ot
Kersti Lundin
REFERENCE: O-004
KERSTI LUNDIN, Sahlgrenska University Hospital, Göteborg, Sweden
The same birth rates following in-vitro fertilisation can be achieved with single embryo transfer as with double transfer, according to the findings of a study from Sweden. A retrospective investigation looked at whether multiple births, and other risk factors associated with double embryo transfer, can be avoided when single transfer is used whilst still achieving the same live delivery rates. Sarah Maxwell talked with study author Kersti Lundin during the European fertility conference in Lyon.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer
Pierre Laurent-Puig
Bill Hait
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.